Citation

Jain A, Marrie RA, Shafer LA, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Fisk JD, Bernstein CN. Crohns Colitis 360 2020; 2(1): otz053.

Affiliation

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Copyright

(Copyright © 2020, Oxford University Press)

DOI

10.1093/crocol/otz053

PMID

32003760

PMCID

PMC6977711

Abstract

We conducted a systematic review and a fixed-effects meta-analysis to determine whether incident adverse psychiatric events (APE) including depression, anxiety, psychosis, or suicide were associated with biologic therapy in IBD. Six randomized controlled trials and a cohort study met criteria, reporting an incidence of APE in 4,882 patients. The risk difference per 100 person-months of any APE with a biologic medication was 0.01 (95% confidence interval = 0.00-0.02). There was insufficient evidence available in randomized controlled trials to conclude that biologic therapy in IBD is associated with an increased incidence of APE.

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

Language: en

Keywords

adverse psychiatric events; biologic therapy; meta-analysis; randomized controlled trials